1. Which of the following medications improves hyperglycemia via inhibition of SGLT-2 transporters in the kidney, thus resulting in glucosuria?
A. Ertugliflozin
B. Semaglutide
C. Soliqua
D. Xultophy
2. Which of the following agents is an SGLT-2 inhibitor that carries an indication to reduce the risk of CV death in adults with T2D and established cardiovascular disease?
A. Liraglutide
B. Ertugliflozin
C. Dapagliflozin
D. Empagliflozin
3. All of the following are warnings or precautions listed in the prescribing information for ertugliflozin EXCEPT:
A. Urosepsis and pyelonephritis
B. Pancreatitis
C. Lower limb amputation
D. Diabetic ketoacidosis
4. Which of the following is/are a mechanism of GLP-1 receptor agonists in the setting of T2D?
A. Stimulation of glucose-dependent insulin secretion
B. Suppression of glucagon release from pancreatic α-cells
C. Delayed gastric emptying
D. All of the above
5. Which of the following GLP-1 receptor agonists is administered once daily?
A. Semaglutide
B. Liraglutide
C. Dulaglutide
D. Exenatide
6. Which of the following insulin products is considered a “follow on” biologic?
A. Soliqua
B. Xultophy
C. Basaglar
D. Tresiba
7. You are considering recommending Xultophy for a patient with T2D. What is the maximum number of insulin units that can be administered with this fixed-ratio combination product?
A. 30 units
B. 40 units
C. 50 units
D. 60 units
8. ZA is a 64-year-old woman with T2D. Her primary care provider has requested a recommendation for an add-on agent to background metformin therapy due to ZA's elevated A1C (7.7%). ZA has a history of hypertension, NYHA class II heart failure (HF), and albuminuria. Based on the information provided, which of the following would be the MOST APPROPRIATE antihyperglycemic therapy to recommend as add-on to metformin (assuming there are no contraindications to therapy)?
A. Addition of an SGLT-2 inhibitor with evidence of decreased HF and chronic kidney disease progression
B. Addition of a GLP-1 receptor agonist with proven CVD benefit
C. Addition of a DPP-4 inhibitor
D. Addition of a sulfonylurea
9. TL is a 54-year-old man with T2D. He was previously well controlled on metformin monotherapy, but his A1C has been increasing over the last year. His A1C today is 8.1%. TL's past medical history is positive for hypertension, hyperlipidemia, chronic kidney disease (CKD), and a myocardial infarction (MI) 18 months ago. Based on TL's established ASCVD it is decided to add either an SGLT-2 inhibitor or GLP-1 receptor agonist to his regimen. Based on TL's kidney function (eGFR of 41 mL/min/1.73 m2 ) it is decided to start him on a GLP-1 receptor agonist. According to the 2019 ADA Standards of Care, which GLP-1 receptor agonist is given highest preference for use in patients with established ASCVD?
A. Semaglutide
B. Exenatide extended release
C. Dulaglutide
D. Liraglutide
10. The 2019 ADA Standards of Care stresses that individualized glycemic goals be established for older adults and that they are periodically adjusted in consideration of:
A. Coexisting chronic illness
B. Cognitive function
C. Functional status
D. All of the above
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
21. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
22. Will the information presented cause you to change your practice?
A. Yes
B. No
23. Are you committed to making these changes?
A. Yes
B. No
24. As a result of this activity, did you learn something new?
A. Yes
B. No
25. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
26. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20